The largest holder of BioMarin Pharmaceutical stock is BlackRock Advisors LLC, with 18.7 million shares (9.68% of the company), worth about $1.22 billion as of September 25, 2026. The 10 largest holders together own 51.9%.
In Q2 2026, 592 institutional holdings reports listed shares worth $12.30 billion.
Insiders reported 51 transactions in the last two years: 10 sales worth $4.31 million and no purchases. The newest one on file is from May 7, 2026 (Friberg Gregory R, Officer).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through May 7, 2026.

2026Q2
| Holder | Shares | % of company | Value |
|---|---|---|---|
| BlackRock Advisors LLC | 18.7 million | 9.68% | $1.2B |
| Dodge & Cox | 14.8 million | 7.67% | $968.0M |
| PRIMECAP Management Co. | 14.2 million | 7.33% | $926.0M |
| Vanguard Capital Management LLC | 8.7 million | 4.52% | $570.0M |
| Vanguard Portfolio Management LLC | 8.6 million | 4.47% | $564.0M |
| Norges Bank (13F) | 8.2 million | 4.24% | $535.0M |
| State Street Corporation | 7.8 million | 4.03% | $509.0M |
| Viking Global Investors LP | 7.6 million | 3.94% | $497.0M |
| Vestal Point Capital LP | 6.0 million | 3.11% | $393.0M |
| AQR Capital Management LLC | 5.7 million | 2.94% | $372.0M |
As of September 25, 2026.
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 592 | – | $12.3B |
| Q1 2026 | 586 | 184.0 million | $10.4B |
| Q4 2025 | 580 | 189.0 million | $11.2B |
| Q3 2025 | 618 | 180.0 million | $9.8B |
| Q2 2025 | 630 | 186.0 million | $10.2B |
| Q1 2025 | 628 | 187.0 million | $13.1B |
| Q4 2024 | 596 | 184.0 million | $12.1B |
| Q3 2024 | 614 | 184.0 million | $12.9B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Friberg Gregory R | May 7, 2026 | Officer | Sale at price 53.85 per share. | $176,682 |
| Davis George Eric | Mar 16, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Guyer Charles Greg | Mar 16, 2026 | Chief Technology Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Hardy Alexander | Mar 16, 2026 | Chief Executive Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Hubbard Cristin | Mar 16, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Friberg Gregory R | Mar 16, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Mueller Brian R | Mar 16, 2026 | Chief Financial Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Guyer Charles Greg | Mar 11, 2026 | Chief Technology Officer | Sale at price 60.46 per share. | $996,744 |
| Davis George Eric | Feb 26, 2026 | Officer | Sale at price 61.36 per share. | $1.6M |
| Friberg Gregory R | Feb 26, 2026 | Officer | Sale at price 60.38 per share. | $381,937 |
| Davis George Eric | Feb 25, 2026 | Officer | Stock Award(Grant) at price 0.00 per share. | – |
| Guyer Charles Greg | Feb 25, 2026 | Chief Technology Officer | Stock Award(Grant) at price 0.00 per share. | – |
Newest 12 of 51 insider transactions in the last two years.
BlackRock Advisors LLC, with 9.68% of the company (as of September 25, 2026). Next: Dodge & Cox (7.67%) and PRIMECAP Management Co. (7.33%).
592 institutional holdings reports listed BioMarin Pharmaceutical shares in Q2 2026 worth $12.30 billion.
In the last two years insiders reported 10 sales and no purchases (51 transactions in all); the newest on file is from May 7, 2026.